PortalPublikationenUpdate Breast Cancer 2021 Part 1 - Prevention and Early Stag...

Update Breast Cancer 2021 Part 1 - Prevention and Early Stages

Standard

Update Breast Cancer 2021 Part 1 - Prevention and Early Stages. / Stickeler, Elmar; Aktas, Bahriye; Behrens, Annika; Belleville, Erik; Ditsch, Nina; Fasching, Peter A; Fehm, Tanja N; Hartkopf, Andreas D; Jackisch, Christian; Janni, Wolfgang; Kolberg-Liedtke, Cornelia; Kolberg, Hans-Christian; Lüftner, Diana; Lux, Michael P; Müller, Volkmar; Schneeweiss, Andreas; Schütz, Florian; Schulmeyer, Carla E; Tesch, Hans; Thomssen, Christoph; Uleer, Christoph; Untch, Michael; Welslau, Manfred; Wöckel, Achim; Wurmthaler, Lena A; Würstlein, Rachel; Thill, Marc.

in: GEBURTSH FRAUENHEILK, Jahrgang 81, Nr. 5, 05.2021, S. 526-538.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Stickeler, E, Aktas, B, Behrens, A, Belleville, E, Ditsch, N, Fasching, PA, Fehm, TN, Hartkopf, AD, Jackisch, C, Janni, W, Kolberg-Liedtke, C, Kolberg, H-C, Lüftner, D, Lux, MP, Müller, V, Schneeweiss, A, Schütz, F, Schulmeyer, CE, Tesch, H, Thomssen, C, Uleer, C, Untch, M, Welslau, M, Wöckel, A, Wurmthaler, LA, Würstlein, R & Thill, M 2021, 'Update Breast Cancer 2021 Part 1 - Prevention and Early Stages', GEBURTSH FRAUENHEILK, Jg. 81, Nr. 5, S. 526-538. https://doi.org/10.1055/a-1464-0953

APA

Stickeler, E., Aktas, B., Behrens, A., Belleville, E., Ditsch, N., Fasching, P. A., Fehm, T. N., Hartkopf, A. D., Jackisch, C., Janni, W., Kolberg-Liedtke, C., Kolberg, H-C., Lüftner, D., Lux, M. P., Müller, V., Schneeweiss, A., Schütz, F., Schulmeyer, C. E., Tesch, H., ... Thill, M. (2021). Update Breast Cancer 2021 Part 1 - Prevention and Early Stages. GEBURTSH FRAUENHEILK, 81(5), 526-538. https://doi.org/10.1055/a-1464-0953

Vancouver

Stickeler E, Aktas B, Behrens A, Belleville E, Ditsch N, Fasching PA et al. Update Breast Cancer 2021 Part 1 - Prevention and Early Stages. GEBURTSH FRAUENHEILK. 2021 Mai;81(5):526-538. https://doi.org/10.1055/a-1464-0953

Bibtex

@article{a4678e26aeb4466facf5fa20580bcf4c,
title = "Update Breast Cancer 2021 Part 1 - Prevention and Early Stages",
abstract = "This review summarises not only the latest evidence on prevention, but also the current research on the treatment of early-stage breast cancer patients. Recent years have seen a growing body of evidence on the risk of high- and moderate-penetrance breast cancer susceptibility genes. A large international consortium has now been able to further refine the answer to the question of the significance of the so-called panel genes. Moreover, the data on treatment selection regarding endocrine efficacy and the decision for or against chemotherapy have also been advanced markedly. There is also new data on adjuvant CDK4/6 (cyclin-dependent kinase 4/6) inhibitors, which are standard in first-line treatment in patients with metastatic HER2-negative, hormone receptor-positive (HR+) breast cancer. For other therapies such as immune checkpoint inhibitors, which have successfully improved the rate of pathologic complete response (pCR) in neoadjuvant treatment settings for patients with triple-negative breast cancer (TNBC), there is a growing understanding of the quality of life and side effects. This is especially important in situations where patients could possibly be cured without such a regimen.",
author = "Elmar Stickeler and Bahriye Aktas and Annika Behrens and Erik Belleville and Nina Ditsch and Fasching, {Peter A} and Fehm, {Tanja N} and Hartkopf, {Andreas D} and Christian Jackisch and Wolfgang Janni and Cornelia Kolberg-Liedtke and Hans-Christian Kolberg and Diana L{\"u}ftner and Lux, {Michael P} and Volkmar M{\"u}ller and Andreas Schneeweiss and Florian Sch{\"u}tz and Schulmeyer, {Carla E} and Hans Tesch and Christoph Thomssen and Christoph Uleer and Michael Untch and Manfred Welslau and Achim W{\"o}ckel and Wurmthaler, {Lena A} and Rachel W{\"u}rstlein and Marc Thill",
note = "The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ).",
year = "2021",
month = may,
doi = "10.1055/a-1464-0953",
language = "English",
volume = "81",
pages = "526--538",
journal = "GEBURTSH FRAUENHEILK",
issn = "0016-5751",
publisher = "Georg Thieme Verlag KG",
number = "5",

}

RIS

TY - JOUR

T1 - Update Breast Cancer 2021 Part 1 - Prevention and Early Stages

AU - Stickeler, Elmar

AU - Aktas, Bahriye

AU - Behrens, Annika

AU - Belleville, Erik

AU - Ditsch, Nina

AU - Fasching, Peter A

AU - Fehm, Tanja N

AU - Hartkopf, Andreas D

AU - Jackisch, Christian

AU - Janni, Wolfgang

AU - Kolberg-Liedtke, Cornelia

AU - Kolberg, Hans-Christian

AU - Lüftner, Diana

AU - Lux, Michael P

AU - Müller, Volkmar

AU - Schneeweiss, Andreas

AU - Schütz, Florian

AU - Schulmeyer, Carla E

AU - Tesch, Hans

AU - Thomssen, Christoph

AU - Uleer, Christoph

AU - Untch, Michael

AU - Welslau, Manfred

AU - Wöckel, Achim

AU - Wurmthaler, Lena A

AU - Würstlein, Rachel

AU - Thill, Marc

N1 - The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ).

PY - 2021/5

Y1 - 2021/5

N2 - This review summarises not only the latest evidence on prevention, but also the current research on the treatment of early-stage breast cancer patients. Recent years have seen a growing body of evidence on the risk of high- and moderate-penetrance breast cancer susceptibility genes. A large international consortium has now been able to further refine the answer to the question of the significance of the so-called panel genes. Moreover, the data on treatment selection regarding endocrine efficacy and the decision for or against chemotherapy have also been advanced markedly. There is also new data on adjuvant CDK4/6 (cyclin-dependent kinase 4/6) inhibitors, which are standard in first-line treatment in patients with metastatic HER2-negative, hormone receptor-positive (HR+) breast cancer. For other therapies such as immune checkpoint inhibitors, which have successfully improved the rate of pathologic complete response (pCR) in neoadjuvant treatment settings for patients with triple-negative breast cancer (TNBC), there is a growing understanding of the quality of life and side effects. This is especially important in situations where patients could possibly be cured without such a regimen.

AB - This review summarises not only the latest evidence on prevention, but also the current research on the treatment of early-stage breast cancer patients. Recent years have seen a growing body of evidence on the risk of high- and moderate-penetrance breast cancer susceptibility genes. A large international consortium has now been able to further refine the answer to the question of the significance of the so-called panel genes. Moreover, the data on treatment selection regarding endocrine efficacy and the decision for or against chemotherapy have also been advanced markedly. There is also new data on adjuvant CDK4/6 (cyclin-dependent kinase 4/6) inhibitors, which are standard in first-line treatment in patients with metastatic HER2-negative, hormone receptor-positive (HR+) breast cancer. For other therapies such as immune checkpoint inhibitors, which have successfully improved the rate of pathologic complete response (pCR) in neoadjuvant treatment settings for patients with triple-negative breast cancer (TNBC), there is a growing understanding of the quality of life and side effects. This is especially important in situations where patients could possibly be cured without such a regimen.

U2 - 10.1055/a-1464-0953

DO - 10.1055/a-1464-0953

M3 - SCORING: Journal article

C2 - 34035547

VL - 81

SP - 526

EP - 538

JO - GEBURTSH FRAUENHEILK

JF - GEBURTSH FRAUENHEILK

SN - 0016-5751

IS - 5

ER -